3 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
In this pilot study, we are setting on to investigate the differential effects of the VDR activator paricalcitol versus calcitriol on peritoneal transport, peritoneal inflammation and peritoneal defense parameters in PD patients.
The purpose of this study is to assess the anti-inflammatory effects of Indacaterol/glycopyrronium/Mometasone (QVM) 150/50/80 µg once daily versus Indacaterol/Mometasone (QMF) 150/160 µg once daily on the allergen-induced late asthmatic response in…